EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Read More

EHA 2021: updates in myeloid malignancies

VJHemOnc is excited to bring you the latest updates from research investigating the treatment and management of myeloid malignancies, as…

Read More

FDA approves daratumumab and hyaluronidase-fihj for sixth multiple myeloma indication

Last week saw the FDA approval of daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with…

Read More

Managing CTCL: UK patient experience

Case study presentations w/ Prof. Julia Scarisbrick & Dr Wendy Osborne. This feature is commissioned and fully funded by Takeda UK…

Read More

Treating Newly Diagnosed AML: Hypothetical Patient Case Studies

This promotional feature has been sponsored by Pfizer and is intended for healthcare professionals. Relevant prescribing information can be found…

Read More

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Read More

Ide-cel receives FDA approval for relapsed/refractory multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell (CAR-T) therapy, for…

Read More

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

Read More
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals